Excision BioTherapeutics Awarded a “Fierce 15” Biotech Company of 2024
Company Applying its Proprietary CRISPR Technology to Address Recurrent Infections in Herpes Simplex Keratitis (HSK)
Company Applying its Proprietary CRISPR Technology to Address Recurrent Infections in Herpes Simplex Keratitis (HSK)